HF-158K1 by HighField Biopharmaceuticals for Colon Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Colon Cancer.

Non-alcoholic beers may be a happy hour for bacteria, study warns

Researchers find that low-alcoholic beers can inhibit bacterial growth, while non-alcoholic beers are more susceptible. Storage temperature and alcohol content are the main factors determining

October 27, 2023

Pandemic impact: Significant rise in sleep disturbances among children and adolescents worldwide

The global prevalence of sleep disturbances in children and adolescents during the COVID-19 pandemic.

January 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

HF-158K1 by HighField Biopharmaceuticals for Colon Cancer: Likelihood of Approval

Non-alcoholic beers may be a happy hour for bacteria, study warns

Discovery of key RSV immune evasion mechanism offers hope for new treatments

Pandemic impact: Significant rise in sleep disturbances among children and adolescents worldwide

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe